A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association

被引:345
作者
Ndumele, Chiadi E.
Neeland, Ian J.
Tuttle, Katherine R.
Chow, Sheryl L.
Mathew, Roy O.
Khan, Sadiya S.
Coresh, Josef
Baker-Smith, Carissa M.
Carnethon, Mercedes R.
Despres, Jean-Pierre
Ho, Jennifer E.
Joseph, Joshua J.
Kernan, Walter N.
Khera, Amit
Kosiborod, Mikhail N.
Lekavich, Carolyn L.
Lewis, Eldrin F.
Lo, Kevin B.
Ozkan, Bige
Palaniappan, Latha P.
Patel, Sonali S.
Pencina, Michael J.
Powell-Wiley, Tiffany M.
Sperling, Laurence S.
Virani, Salim S.
Wright, Jackson T.
Singh, Radhika Rajgopal
Elkind, Mitchell S. V.
Rangaswami, Janani
Amer Heart Assoc
机构
关键词
AHA Scientific Statements; cardiovascular diseases; diabetes; type; 2; heart diseases; kidney failure; chronic; metabolic syndrome; obesity; social determinants of health; CORONARY-ARTERY CALCIUM; PEPTIDE-1 RECEPTOR AGONISTS; LIFE-STYLE INTERVENTION; BLOOD-PRESSURE CONTROL; BODY-MASS INDEX; RISK-FACTORS; TASK-FORCE; NATRIURETIC PEPTIDE; DIABETES-MELLITUS; WEIGHT-LOSS;
D O I
10.1161/CIR.0000000000001186
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led to the conceptualization of cardiovascular-kidney-metabolic syndrome. The confluence of metabolic risk factors and chronic kidney disease within cardiovascular-kidney-metabolic syndrome is strongly linked to risk for adverse cardiovascular and kidney outcomes. In addition, there are unique management considerations for individuals with established cardiovascular disease and coexisting metabolic risk factors, chronic kidney disease, or both. An extensive body of literature supports our scientific understanding of, and approach to, prevention and management for individuals with cardiovascular-kidney-metabolic syndrome. However, there are critical gaps in knowledge related to cardiovascular-kidney-metabolic syndrome in terms of mechanisms of disease development, heterogeneity within clinical phenotypes, interplay between social determinants of health and biological risk factors, and accurate assessments of disease incidence in the context of competing risks. There are also key limitations in the data supporting the clinical care for cardiovascular-kidney-metabolic syndrome, particularly in terms of early-life prevention, screening for risk factors, interdisciplinary care models, optimal strategies for supporting lifestyle modification and weight loss, targeting of emerging cardioprotective and kidney-protective therapies, management of patients with both cardiovascular disease and chronic kidney disease, and the impact of systematically assessing and addressing social determinants of health. This scientific statement uses a crosswalk of major guidelines, in addition to a review of the scientific literature, to summarize the evidence and fundamental gaps related to the science, screening, prevention, and management of cardiovascular-kidney-metabolic syndrome.
引用
收藏
页码:1636 / 1664
页数:29
相关论文
共 209 条
[1]   Initial Decline (Dip) in Estimatec Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF [J].
Adamson, Carly ;
Docherty, Kieran F. ;
Heerspink, Hiddo J. L. ;
de Boer, Rudolf A. ;
Damman, Kevin ;
Inzucchi, Silvio E. ;
Kober, Lars ;
Kosiborod, Mikhail N. ;
Martinez, Felipe A. ;
Petrie, Mark C. ;
Ponikowski, Piotr ;
Sabatine, Marc S. ;
Schou, Morten ;
Solomon, Scott D. ;
Verma, Subodh ;
Bengtsson, Olof ;
Langkilde, Anna Maria ;
Sjostrand, Mikaela ;
Vaduganathan, Muthiah ;
Jhund, Pardeep S. ;
McMurray, John J., V .
CIRCULATION, 2022, 146 (06) :438-449
[2]   Kidney Disease and Increased Mortality Risk in Type 2 Diabetes [J].
Afkarian, Maryam ;
Sachs, Michael C. ;
Kestenbaum, Bryan ;
Hirsch, Irl B. ;
Tuttle, Katherine R. ;
Hinnmelfarb, Jonathan ;
de Boer, Ian H. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (02) :302-308
[3]   Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis [J].
Agarwal, Rajiv ;
Filippatos, Gerasimos ;
Pitt, Bertram ;
Anker, Stefan D. ;
Rossing, Peter ;
Joseph, Amer ;
Kolkhof, Peter ;
Nowack, Christina ;
Gebel, Martin ;
Ruilope, Luis M. ;
Bakris, George L. .
EUROPEAN HEART JOURNAL, 2022, 43 (06) :474-+
[4]   Accounting for the Competing Risk of Death to Predict Kidney Failure in Adults With Stage 4 Chronic Kidney Disease [J].
Al-Wahsh, Huda ;
Tangri, Navdeep ;
Quinn, Rob ;
Liu, Ping ;
Ferguson, Thomas ;
Fiocco, Marta ;
Lam, Ngan N. ;
Tonelli, Marcello ;
Ravani, Pietro .
JAMA NETWORK OPEN, 2021, 4 (05) :E219225
[5]   Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study [J].
Amdur, Richard L. ;
Feldman, Harold I. ;
Dominic, Elizabeth A. ;
Anderson, Amanda H. ;
Beddhu, Srinivasan ;
Rahman, Mahboob ;
Wolf, Myles ;
Reilly, Muredach ;
Ojo, Akinlolu ;
Townsend, Raymond R. ;
Go, Alan S. ;
He, Jiang ;
Xie, Dawei ;
Thompson, Sally ;
Budoff, Matthew ;
Kasner, Scott ;
Kimmel, Paul L. ;
Kusek, John W. ;
Raj, Dominic S. ;
Fink, Jeffrey ;
Appel, Lawrence J. ;
Lash, James P. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (03) :344-353
[6]  
Amsterdam EA, 2014, J AM COLL CARDIOL, V64, P2713, DOI [10.1016/j.jacc.2014.09.017, 10.1016/j.jacc.2014.10.011, 10.1161/CIR.0000000000000134, 10.1016/j.jacc.2014.09.016]
[7]   Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease [J].
Anderegg, Maxwell D. ;
Gums, Tyler H. ;
Uribe, Liz ;
MacLaughlin, Eric J. ;
Hoehns, James ;
Bazaldua, Oralia V. ;
Ives, Timothy J. ;
Hahn, David L. ;
Coffey, Christopher S. ;
Carter, Barry L. .
PHARMACOTHERAPY, 2018, 38 (03) :309-318
[8]  
Heidenreich Paul A, 2022, Circulation, V145, pe895, DOI [10.1161/CIR.0000000000001073, 10.1161/CIR.0000000000001063]
[10]  
[Anonymous], 2023, Diabetes Care, V46, pS1